Search

Search Constraints

You searched for: Author/Creator Zielinski, C.C.

Search Results

1. 1800 Final results for overall survival (OS), the primary endpoint of the CECOG TURANDOT prospective randomised trial evaluating bevacizumab-paclitaxel (BEV-PAC) vs BEV-capecitabine (CAP) for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC). Issue 3 (September 2015)

5. 447 Extended Analysis for Cancer Treatment (EXACT): Interim analysis of a prospective precision medicine trial. (September 2015)

6. Decreased body mass index is associated with impaired survival in lung cancer patients with brain metastases: A retrospective analysis of 624 patients. (10th May 2017)